share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 20 07:03
Summary by Moomoo AI
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on February 20, 2024, the publication of new data in the International Journal of Molecular Sciences demonstrating that its investigational drug opaganib significantly improves long-term survival in a mouse model of lung damage following ionizing radiation exposure. The study indicates opaganib's potential as a medical countermeasure against radiation-induced lung inflammation and fibrosis. Opaganib, a selective sphingosine kinase-2 (SPHK2) inhibitor, is being developed for multiple indications, including Acute Radiation Syndrome (ARS), COVID-19, and oncology. The U.S. National Institutes of Health's Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for its Product Development Program. The drug, which is easy to administer and has a five-year shelf-life, could be stockpiled by governments for use in radiological or nuclear incidents, pending FDA approval. The publication also highlights opaganib's potential benefits in cancer radiotherapy and its host-directed mechanism, which may maintain efficacy against emerging viral variants.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on February 20, 2024, the publication of new data in the International Journal of Molecular Sciences demonstrating that its investigational drug opaganib significantly improves long-term survival in a mouse model of lung damage following ionizing radiation exposure. The study indicates opaganib's potential as a medical countermeasure against radiation-induced lung inflammation and fibrosis. Opaganib, a selective sphingosine kinase-2 (SPHK2) inhibitor, is being developed for multiple indications, including Acute Radiation Syndrome (ARS), COVID-19, and oncology. The U.S. National Institutes of Health's Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for its Product Development Program. The drug, which is easy to administer and has a five-year shelf-life, could be stockpiled by governments for use in radiological or nuclear incidents, pending FDA approval. The publication also highlights opaganib's potential benefits in cancer radiotherapy and its host-directed mechanism, which may maintain efficacy against emerging viral variants.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more